BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/21/2024 7:25:52 AM | Browse: 68 | Download: 216
 |
Received |
|
2023-12-12 13:47 |
|
Peer-Review Started |
|
2023-12-12 13:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-03-09 20:18 |
|
Revised |
|
2024-03-22 15:49 |
|
Second Decision |
|
2024-04-17 02:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-04-17 07:50 |
|
Articles in Press |
|
2024-04-17 07:50 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-04-26 10:19 |
|
Publish the Manuscript Online |
|
2024-05-21 07:25 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Leonardo S Lino-Silva, Sabrina B Martínez-Villavicencio and Luisa F Rivera-Moncada |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Leonardo S Lino-Silva, MSc, Director, Director, Professor, Senior Researcher, Department of Pathology Oncology, National Cancer Institute (Mexico), Av. San fernando 22, Sección XVI, Tlalpan, Mexico City 14080, Mexico. saul.lino.sil@gmail.com |
| Key Words |
Primary central nervous system lymphoma; Zanubrutinib; Bruton’s tyrosine kinase; Prognosis; Myeloid differentiation primary response 88 gene; Cluster of differentiation 79B gene |
| Core Tip |
The combination of zanubrutinib with high-dose methotrexate shows promise as a therapeutic approach for primary central nervous system lymphoma (PCNSL). In this study involving 19 patients, the treatment demonstrated a notable 84.2% overall response rate with manageable adverse events. The presence of circulating tumor DNA in cerebrospinal fluid emerged as a potential tool for monitoring treatment response. These findings are optimistic, but research in larger patient groups is crucial to validate outcomes and assess long-term effects, especially in different molecular subtypes of PCNSL. |
| Publish Date |
2024-05-21 07:25 |
| Citation |
<p>Lino-Silva LS, Martínez-Villavicencio SB, Rivera-Moncada LF. Bruton’s tyrosine kinase inhibitors in primary central nervous system lymphoma: New hopes on the horizon. <i>World J Clin Oncol</i> 2024; 15(5): 587-590</p> |
| URL |
https://www.wjgnet.com/2218-4333/full/v15/i5/587.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v15.i5.587 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
